Oncology ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny ASCO is always an interesting show for Kite, the Gilead Sciences subsidiary focused on cell therapy.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.